Congress reports

ESMO 2020 Lung Cancer – virtual

ESMO 2020 Solid Tumours – virtual

English

English

Preface – ESMO 2020

Immune checkpoint inhibition: chemotherapy-free regimens & new PD-1 inhibitors on the horizon

Early-stage lung cancer: noteworthy findings for different types of therapy

Determinants of treatment success in small-cell lung cancer

Innovative and established approaches for patients with uncommon mutations

EGFR-targeted options in a changing treatment landscape

Interview – Malignant mesothelioma: implementation of immunotherapy-based standards

Interview – Exploring interactions between radiotherapy and the immune system

English

English

Milestones of PD-1 inhibition in gastric and esophageal cancer

Getting innovation from the laboratories into clinical practice

Ovarian cancer: taking PARP inhibition one step further

Novel combination approaches in various solid tumors

Download
ESMO Lung Cancer

Slide Kit PD-1/PD-L1 and PARP inhibition in NSCLC

Full report (english)

Download
ESMO Solid Tumours

Slide Kit Pd-1/PD-L1 and PARP inhibition on GI and ovarian cancers

Coming soon full report (english)

Previous Congresses

EHA 2020 – virtual

English

Preface – EHA 2020

Waldenström’s macroglobulinemia: BTK inhibition and other treatments

Optimizing timing, efficacy and tolerability in chronic lymphocytic leukemia

Changing paradigms in the management of mantle cell lymphoma

Targeted approaches in various B-cell malignancies

Cold agglutinin disease: on the road to new insights and potential treatment options

Patient and disease characteristics in a small CAD cohort

Paroxysmal nocturnal hemoglobinuria: improving outcomes with novel strategies

German

Paroxysmale nächtliche Hämoglobinurie: verbesserte Ergebnisse durch neuartige Strategien

Kälteagglutininkrankheit: auf dem Weg zu neuen Einblicken und potenziellen Therapieoptionen

Patienten- und Krankheitscharakteristika in einer kleinen CAD-Kohorte

French

Hémoglobinurie paroxystique nocturne: améliorer les résultats grâce à de nouvelles stratégies

Maladie des agglutinines froides: vers de nouveaux acquis et de nouvelles options thérapeutiques possibles

Caractéristiques des patients et de la maladie dans une petite cohorte atteinte de la MAF

ASCO 2020 – virtual

English

Preface ASCO 2020

NSCLC with MET alterations: molecular insights and innovative treatments

Immune checkpoint inhibition: comprehensive benefits, but not devoid of risks

EGFR-mutated disease: early combinations and new approaches in exon 20 insertion-positive lung cancer

Improving outcomes in the early-stage setting with (neo)adjuvant strategies

Present and future perspectives of anti-angiogenic therapy

COVID-19 in patients with thoracic cancers: TERAVOLT

Rare mutations: HER2, RET, ALK, BRAF

Small-cell lung cancer: moving the limits further

Mandarin

序言

伴有MET改变的NSCLC：分子见解和创新治疗

免疫检查点抑制：综合获益，但并非没有风险

EGFR突变疾病：外显子20插入阳性肺癌的早期组合和新方法

（新）辅助策略改善早期条件下的结果

抗血管生成疗法的现状和未来展望

患有胸部癌症的COVID-19患者：TERAVOLT

罕见突变：HER2、RET、ALK和BRAF

小细胞肺癌：进一步突破极限

Japanese

巻頭言

MET遺伝子変異陽性NSCLC：分子レベルの理解と新規治療薬

免疫チェックポイント阻害：包括的な利点はあるが、リスクがないわけではない

EGFR遺伝子変異陽性がん：エクソン20挿入陽性の肺がんに対する早期併用療法と新たな治療法

早期がんの転帰を改善するための（術前）術後補助療法による戦略

抗血管新生療法の現状と今後の展望

胸部がん患者にみられるCOVID-19：TERAVOLT

まれな遺伝子変異：HER2、RET、ALK、BRAF

小細胞肺がん：限界をさらに広げる

English

Preface

PD-1 inhibition in gastric and esophageal cancer, hepatocellular carcinoma, and urothelial carcinoma

Potential role of the microbiome in carcinogenesis and response to checkpoint inhibition

PARP inhibition in gynecological cancers: recent insights

New applications of PARP inhibitors

Increasing PARP inhibitor activity via several mechanisms of action

Mandarin

序言

胃癌和食管癌、肝细胞癌以及尿路上皮癌中的PD-1抑制

微生物组在癌变和对检查点抑制的应答中的潜在作用

妇科癌症中的PARP抑制：最新见解

PARP抑制剂的新应用

通过多种作用机制提高PARP抑制剂活性

ESMO 2019 Lung Cancer – Barcelona

English

Preface

Checkpoint inhibition in non-small-cell lung cancer: expanding the range of options

EGFR-positive tumors: the issue of optimal therapy across several lines

Frontline combinations of EGFR- and angiogenesis-targeted agents

Exploring synergy between anti-angiogenic drugs and immunotherapy

Innovations in the setting of rare mutations: ALK, ROS1, NTRK, NRG1

CNS disease does not preclude successful treatment

Even infrequent actionable drivers are important

Emerging survival benefits in the small-cell setting

Mandarin

序言

非小细胞肺癌的检查点抑制：扩大选择范围

EGFR阳性肿瘤：多线中的最佳疗法问题

EGFR和血管生成靶向药物的前线组合

探索抗血管生成药物与免疫疗法之间的协同作用

罕见突变ALK、ROS1、NTRK、NRG1条件下的创新

CNS疾病不妨碍成功治疗

即便是罕见的可操作驱动因子也至关重要

小细胞条件下的新兴生存获益

Japanese

巻頭言 – 臨床医の皆様へ

非小細胞肺がんへの免疫チェックポイント阻害薬：広がる選択肢

EGFR遺伝子変異陽性肺がん：あらゆる治療ラインにわたる至適治療にかかわる問題点

EGFR TKIと血管新生阻害薬を併用するフロントライン治療

血管新生阻害薬と免疫チェックポイント阻害薬とのシナジー効果に関する調

ALK、ROS1、NTRK、NRG1といったまれな遺伝子変異陽性肺がんへの画期的な検査法

CNS病変の存在は治療成功の妨げにならない

まれなドライバー変異であっても重要性は高い

小細胞肺がんへの延命効果

ASCO 2019 – Chicago

English

Preface – ASCO 2019

Early-stage NSCLC: promising (neo)adjuvant approaches

Novel first-line options and other insights in EGFR-mutant lung cancer

Trial updates and new biomarkers in the field of immunotherapy

Interview: Blood-based testing in ALK-positive disease

Rare mutations: taking treatment one step further

Small-cell tumors: improvements in the second-line setting

Expansion of clinical trial enrollment criteria: what would we gain?

Mandarin

序言

早期NSCLC：有前景的（新）辅助方法

EGFR突变肺癌的新一线选择和其他见解

免疫疗法领域的试验更新和新生物标志物

ALK阳性疾病基于血液的检测

罕见突变：使治疗更进一步

小细胞肿瘤：二线条件下的改善

扩展临床试验入选标准：我们将有何收获？

Japanese

巻頭言

早期NSCLC：期待を持てる（ネオ）アジュバント療法

EGFR遺伝子変異陽性肺がんへの新規第一選択薬およびその他の知見

臨床試験の最新結果および免疫療法の新規バイオマーカー

ALK融合遺伝子陽性NSCLCにおける血液検体を用いたリキッドバイオプシー

まれな遺伝子変異：治療を一歩先へ進める

小細胞肺がん：セカンドライン治療の改善

臨床試験の選択基準の緩和：われわれにとっての利点

ELCC 2019 – Geneva

English

Preface – ELCC 2019

Encouraging findings in NTRK-, ROS1– and ALK-positive lung cancer

Interview: Improving accuracy of lung cancer screening

Extensive-disease small-cell tumors: signals of activity

Interview: “We need chemotherapy when rapid responses are required”

Anti-angiogenic combinations excel in later lines

Interview: “We need chemotherapy when rapid responses are required”

Current perspectives in EGFR-targeted therapy

Immunotherapy: analyses elucidating durvalumab & pembrolizumab activity

Mandarin

序言

对于EGFR靶向治疗的当前观点

免疫疗法：分析阐明度伐鲁单抗和派姆单抗活性

NTRK-、ROS1-和ALK-阳性肺癌中令人鼓舞的发现

提高肺癌筛查的准确性

广泛期小细胞肿瘤：活性信号

“当需要快速缓解时，化疗必不可少”

抗血管生成组合在后线中表现优异

Japanese

巻頭言

EGFR阻害薬への現在の評価

免疫療法：デュルバルマブおよびペムブロリズマブの作用が分析により明らかに

NTRK、ROS1、ALKの融合遺伝子陽性肺がんへの良好な成績が判明

肺がん検診の精度を高める

進展型小細胞肺がん：免疫療法の効果のシグナル

「迅速な効果を求める場合には化学療法が必要」

セカンドライン治療以降の血管新生阻害薬の併用療法に良好な結果

ESMO 2018 – Munich

English

Preface – ESMO 2018

Checkpoint inhibition excels in all treatment lines

EGFR-mutant lung cancer: what’s new with respect to activity and resistance?

Interview: Several reasons support sequencing of EGFR TKI treatment

Potent treatment options in ALK– and MET-positive disease

Mandarin

序言

检查点抑制在所有治疗线中表现优异

EGFR突变肺癌：活性和耐药性方面新发现

专访：支持EGFR TKI治疗用药顺序的若干原因

ALK和MET阳性疾病的有效治疗选择

Japanese

巻頭言

すべての治療ラインで免疫チェックポイント阻害薬が優位に

EGFR遺伝子変異陽性肺がん：活性および耐性に関する新たな知見とは？

インタビュー：EGFR TKI療法の順番を重視するいくつかの理由

ALK融合遺伝子変異陽性肺がんおよびMET遺伝子変異陽性肺がんへの効果の高い選択肢

WCLC 2018 – Toronto

English

Preface – WCLC 2018

New data on PD-L1 inhibitor activity and determinants of outcomes in immunotherapy-treated patients

Emerging standards in tumours with rare genetic drivers

Anti-EGFR treatment: real-world experience and clinical trial insights

Interview: Modern agents enable dramatic responses even in phase I trials

Substantial reduction in lung cancer mortality using volume CT screening: the NELSON trial

Multiple approaches for the treatment and prevention of CNS metastases

Mandarin

序言

PD-L1抑制剂活性和免疫治疗患者结果的决定因素相关新数据

具有罕见遗传驱动肿瘤的新兴标准

抗EGFR治疗：实际经验与临床试验见解

访谈：新药即使在I期试验中也能产生惊人缓解

使用体积CT筛查显著降低肺癌死亡率：NELSON试验

患者视角：评估生活质量和肺癌病耻感

治疗和预防CNS转移的多种方法

Japanese

巻頭言

免疫療法を受ける患者の転帰への抗PD-L1抗体薬の活性および決定因子に関する新データ

まれなドライバー遺伝子変異のある腫瘍への新しい標準治療

抗EGFR抗体薬：実臨床での使用経験と治験で得た感想

インタビュー：第I相試験であっても新薬には劇的な効果が見られる

肺がん検診にボリュームCTを用いることで肺がんの死亡率が大幅に低下：NELSON試験

患者の見解：生活の質の評価と肺がんに関わるスティグマ

CNS転移巣への多様な治療法および予防法

ASCO 2018 – Chicago

English

Preface – ASCO 2018

PD-(L)1 inhibition alone and in combination: recent insights into immunotherapy

Immune checkpoint blockade: determinants of treatment success

New data on EGFR-directed TKIs across 3 generations

Interview with Barbara Melosky: “The sequencing question remains”

ALK-positive disease: pushing the borders of treatability

Recent benchmarks in the management of small-cell tumours

Comprehensive sequencing of plasma cell-free DNA permits non-invasive cancer detection

Distinct somatic genome variations in young lung cancer patients

Mandarin

前言

PD-(L)1 单独和联合抑制：近期对免疫疗法的见解

免疫检查点阻滞：治疗成功的决定因素

关于跨 3 个世代的 EGFR 靶向 TKI 的新数据

访谈：“定序问题仍然存在

ALK 阳性疾病：推动可治疗性突破界限

近期小细胞肿瘤管理的基准

通过血浆游离 DNA 的全面测序进行非侵入性癌症检测

年轻肺癌患者的不同体细胞基因组变异

Japanese

序文

PD-(L)1阻害薬の単独療法と併用療法：最新の免疫療法の洞察

免疫チェックポイント遮断：治療成功の成功のカギを握る要素

第3世代EGFRチロシンキナーゼ阻害薬（TKI）最新データ

「シーケンシングの課題」

16 ALK陽性疾患：治療の可能性が広がる

小細胞がんの治療に関する最新ベンチマーク

非浸潤がん検出を可能にする血漿セルフリーDNAの包括的なシーケンシング

若年性肺がん患者における体細胞ゲノムの変異

CSCO 2017 – Xiamen

English
Mandarin

English

Preface – CSCO 2017

Guidelines for the treatment of NSCLC in China: progress and controversies

Diagnosis of EGFR-mutated NSCLC: from guidelines to reality

Different therapies for treatment of squamous cell carcinoma

Optimal strategy for the treatment of EGFR-mutant lung cancer

New insights into the treatment of ALK-mutant-positive NSCLC patients

Determination of clinical responses to immunotherapy

Combination of targeted therapy with radiotherapy for treatment of brain metastasis

Mandarin

序言

中国NSCLC治疗指南：进展与争议

EGFR突变NSCLC的诊断：从指南到现实

治疗鳞状细胞癌的不同疗法

用于治疗EGFR突变肺癌的最佳策略

ALK突变阳性NSCLC患者治疗新见解

免疫疗法临床应答的确定

靶向疗法联合放疗用于治疗脑转移

WCLC 2017 – Yokohama

English

Preface – WCLC 2017

What is new in surgery? Redefining current options

EGFR TKI therapy in specific populations and settings

“We are making steady progress toward better lung cancer control”

Taking anti-EGFR drug treatment further: later lines

Immunotherapy: novel biomarkers on the horizon & news from pivotal trials

Approaching squamous-cell carcinoma in a targeted manner

Malignant mesothelioma: recent data on nintedanib and checkpoint inhibitors

Chemotherapy: new approaches, new settings

Survival is the result of lung cancer screening

Mandarin

序言

外科手术有哪些新方法？重新定义当前选择

特定人群和治疗条件下的EGFR TKI疗法

“我们正朝着更好地控制肺癌稳步迈进”

进一步采取抗EGFR药物治疗：多线

免疫疗法：初露端倪的新型生物标志物与来自关键试验的消息

以靶向方式治疗鳞状细胞癌

恶性间皮瘤：尼达尼布（nintedanib）和检查点抑制剂的相关近期数据

化疗：新方法、新治疗条件

肺癌筛查对生存的积极意义

Japanese

序文

手術の最新情報現在のオプションの再定義

特定の集団と条件でのEGFR TKI治療

「肺癌のより良い管理に向けて着実に進歩しています」

抗EGFR薬治療のさらなる使用：1次治療以降の治療

免疫療法：兆しが見えた新規バイオマーカーとピボタル床試験からのニュース

標的治療による扁平上皮細胞癌のアプローチ

悪性中皮腫：ニンテダニブとチェックポイント阻害薬に関する最新データ

化学療法：新しいアプローチ、新しいセッティング

「生存期間は肺癌スクリーニングの結果です」

ESMO 2017 – Madrid

English

Preface – ESMO 2017

Immunotherapy: once more at the cutting edge of progress

Immunostimulation as a promising approach in SCLC

Randomised findings on CT-based follow-up after resection of early NSCLC

EGFR-mutant lung cancer: sequencing as a major topic in light of new data

Interview: “Survival is the result of multiple treatment lines”

Reaching unprecedented outcome dimensions in malignant mesothelioma

Characteristics and outcomes for SCLC arising from transformation

ALK-positive NSCLC: updates on crizotinib and alectinib

Rare driver mutations: BRAF- and HER2-mutant NSCLC

Mandarin

序言

免疫疗法：再次处于进步前沿

免疫刺激作为有希望的SCLC疗法

早期NSCLC切除后基于CT随访的随机化结果

EGFR突变肺癌：排序根据新数据作为主要话题

专访：生存期受到多条治疗线的影响

获得前所未有规模的恶性间皮瘤结果

转化导致SCLC的特征和结果

ALK阳性NSCLC：克唑替尼和艾乐替尼的更新数据

罕见驱动突变：BRAF和HER2突变NSCLC

Japanese

序文

免疫療法: 進歩の最先端でもう一度

SCLCでの有望なアプローチとしての免疫刺激

早期NSCLCの切除後のCTベースの経過観察に関する無作為化所見

EGFR-変異肺癌：新たなデータを考慮した大きな話題としての優先順位付け

インタビュー：生存は複数の治療ラインの結果である

悪性中皮腫で前例のない転帰範囲に到達

形質転換に起因するSCLCの特性および転帰

ALK-陽性NSCLC：クリゾチニブおよびアレクチニブに関する最新情報

希少ドライバー変異：BRAF-およびHER2-変異NSCLC

ASCO 2017 – Chicago

English

English

Preface – ASCO 2017

EGFR-targeted treatments: insights from the adjuvant to the resistant setting

New standards of care for ALK-positive disease

Reducing the danger that arises from the CNS as a site of progression

Diagnostics of EGFR-mutant disease: biomarkers with significant clinical implications

Established targeted agents taking root in the HER2-positive setting

Further defining the optimal use of immune checkpoint inhibitors

Real-world utility of ctDNA NGS to identify matched targeted therapy

Interview: Lung cancer in China: hurdles and progress

Anti-angiogenic and immunotherapeutic approaches in mesothelioma

Enhancing the profile of KRAS-mutant lung cancer

WCLC 2016 – Vienna

English

English

Preface – WCLC 2016

Notable advances in the field of anti-EGFR therapy

Emerging treatments in ALK-positive NSCLC: new options, but also new challenges

Liquid biopsy in the context of EGFR and other mutations

Immunotherapy: novel anti-PD-L1 antibodies & various combination regimens

Who is a candidate for immunotherapy?

Anti-angiogenesis with nintedanib: activity in mesothelioma, and potential biomarkers

Practice-changing refinements of lung cancer staging

Inhibition of HER2 driver mutations can confer benefits

ESMO 2016 – Copenhagen

English

English

Preface – ESMO 2016

Rare driver mutations: encouraging results in small patient populations

SCLC: genomic alterations pave the way to targeted approaches

No phase III benefit with selumetinib in KRAS-mutant NSCLC

EGFR-targeted therapy: at the right time in the right patient

Targeting angiogenesis can prolong life

Next-generation ALK inhibitors excel after crizotinib failure

Immune checkpoint inhibition: the picture is slowly completing itself

ASCO 2016 – Chicago

English

English

Preface – ASCO 2016

Immunotherapy: updates on clinical trials and other insights

Expanding treatment options in NSCLC patients with rare mutations: ALK, ROS1, MET, BRAF

Lung cancer care in Latin America: evolution of modern therapies and challenges to overcome the existing gaps

Exploring established and novel EGFR-directed agents

“The importance of first-line and second-line targeted agents is obvious”

Mutational analysis: on the road to refined standards

New approaches are raising hope for SCLC patients

ULTIMATE: chemotherapy plus bevacizumab beyond first line

Locally advanced NSCLC: oral vinorelbine shows better safety profile than etoposide

PFS improvement due to local therapy in oligometastatic NSCLC

Similar outcomes obtained with four adjuvant cisplatin-based chemotherapy regimens

ESMO Asia 2015 – Singapore

English
Mandarin

English

Preface – ESMO Asia 2015

EGFR-mutation-positive NSCLC: expanding the data pool for established treatment options

Disease progression on EGFR TKI therapy: what to do after erlotinib, gefitinib and afatinib?

Risks and chances in patients with oligometastatic disease

Immunotherapy: anti-tumour activity despite extensive pretreatment

PD-L1 expression is a nightmare in terms of complexity

Immunotherapy: management of toxicity

Intracranial activity of ceritinib in crizotinib-pretreated and crizotinib-naïve ALK-positive NSCLC patients

Mandarin

序言

EGFR 突变阳性非小细胞肺癌：扩大用于既定治疗方案的数据池

使用 EGFR TKI 疗法后的疾病进展：在埃罗替尼、吉非替尼和阿法替尼之后还有哪些手段？

寡转移疾病患者的风险与机会

免疫疗法：大量预治疗之后令人瞩目的抗肿瘤活性

“PD-L1 表达如噩梦般复杂”

免疫疗法：毒性管理

在经克唑替尼预治疗和未经过克唑替尼治疗的 ALK 阳性非小细胞肺癌患者体内色瑞替尼的颅内活性

English

English

English

English

Download ESMO Lung Cancer

Download ESMO Solid Tumours

Previous Congresses

English

German

French

English

German

French

English

Mandarin

Japanese

English

Mandarin

Japanese

ESMO 2019 Solid Tumours – Barcelona

English

Mandarin

English

Mandarin

ESMO 2019 Lung Cancer – Barcelona

English

Mandarin

Japanese

English

Mandarin

Japanese

ASCO 2019 – Chicago

English

Mandarin

Japanese

English

Mandarin

Download
ESMO Lung Cancer

Download
ESMO Solid Tumours